RT @GoggleDocs: 🔸Post hoc (😉) analysis of LEADER trial in HF does reassure that no differences between HF class 🔹 ⬇️ ☠️ in liraglutide gro…
🔸Post hoc (😉) analysis of LEADER trial in HF does reassure that no differences between HF class 🔹 ⬇️ ☠️ in liraglutide group 🔸No ⬆️hHF in liraglutide group 🔹NYHA class I-III @AskDrShashank @singhak_endo @DrDerekConnolly https://t.co/48mQSqBM2b
リラグルチドの2型糖尿病患者における、主要心血管イベントの抑制効果。 プラセボと比較して、 ・心不全既往あり HR=0.81、95%CI 0.65-1.02 ・心不全既往なし HR=0.88、95%CI 0.78-1.00 LEADER試験の事後解析結果。 PMID:32164886 https://t.co/V6epHtjCcp
【事後解析: LEADER】心血管ハイリスクの2型糖尿病患者へのプラセボと比較したリラグルチド投与による主要心血管イベントへの影響は、心不全の既往(NYHA分類1-3)の有無に影響されなかった。 https://t.co/vejOGsDA6s
Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure https://t.co/xlL6wUhiu5
RT @JACCJournals: New study from the LEADER Trial Investigators find fewer major #CVD-related events in #T2DM adults with and without #hear…
RT @JTLLERGO: 📌LEADER trial: LIRAGLUTIDE 📍 18% had history of NYHA class I to III HF 📍 MACE reduction was consistent in patients with (HR 0…
RT @JACCJournals: New study from the LEADER Trial Investigators find fewer major #CVD-related events in #T2DM adults with and without #hear…
RT @JACCJournals: New study from the LEADER Trial Investigators find fewer major #CVD-related events in #T2DM adults with and without #hear…
RT @JACCJournals: New study from the LEADER Trial Investigators find fewer major #CVD-related events in #T2DM adults with and without #hear…
New study from the LEADER Trial Investigators find fewer major #CVD-related events in #T2DM adults with and without #heartfailure using anti-diabetic medication, liraglutide vs. placebo. https://t.co/2NxLEOtv9L #JACC @HCAMidwest https://t.co/B3IWA5T811
RT @JTLLERGO: 📌LEADER trial: LIRAGLUTIDE 📍 18% had history of NYHA class I to III HF 📍 MACE reduction was consistent in patients with (HR 0…
RT @JTLLERGO: 📌LEADER trial: LIRAGLUTIDE 📍 18% had history of NYHA class I to III HF 📍 MACE reduction was consistent in patients with (HR 0…
RT @CarreteroJuani: Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure | JACC. GLP1r…
RT @SemergenGTDM: Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure | JACC: Journal…
RT @SemergenGTDM: Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure | JACC: Journal…
RT @CarreteroJuani: Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure | JACC. GLP1r…
RT @JTLLERGO: 📌LEADER trial: LIRAGLUTIDE 📍 18% had history of NYHA class I to III HF 📍 MACE reduction was consistent in patients with (HR 0…
RT @JTLLERGO: 📌LEADER trial: LIRAGLUTIDE 📍 18% had history of NYHA class I to III HF 📍 MACE reduction was consistent in patients with (HR 0…
RT @JTLLERGO: 📌LEADER trial: LIRAGLUTIDE 📍 18% had history of NYHA class I to III HF 📍 MACE reduction was consistent in patients with (HR 0…
RT @CarreteroJuani: Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure | JACC. GLP1r…
RT @Drlipid: Cost aside (obviously a major issue), anyone who has diabetes & high CV risk should consider liraglutide or perhaps another GL…
RT @JTLLERGO: 📌LEADER trial: LIRAGLUTIDE 📍 18% had history of NYHA class I to III HF 📍 MACE reduction was consistent in patients with (HR 0…
RT @JTLLERGO: 📌LEADER trial: LIRAGLUTIDE 📍 18% had history of NYHA class I to III HF 📍 MACE reduction was consistent in patients with (HR 0…
@SemergenGTDM
RT @JTLLERGO: 📌LEADER trial: LIRAGLUTIDE 📍 18% had history of NYHA class I to III HF 📍 MACE reduction was consistent in patients with (HR 0…
RT @CarreteroJuani: Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure | JACC. GLP1r…
RT @JTLLERGO: 📌LEADER trial: LIRAGLUTIDE 📍 18% had history of NYHA class I to III HF 📍 MACE reduction was consistent in patients with (HR 0…
RT @JTLLERGO: 📌LEADER trial: LIRAGLUTIDE 📍 18% had history of NYHA class I to III HF 📍 MACE reduction was consistent in patients with (HR 0…
RT @JTLLERGO: 📌LEADER trial: LIRAGLUTIDE 📍 18% had history of NYHA class I to III HF 📍 MACE reduction was consistent in patients with (HR 0…
RT @JTLLERGO: 📌LEADER trial: LIRAGLUTIDE 📍 18% had history of NYHA class I to III HF 📍 MACE reduction was consistent in patients with (HR 0…
RT @JTLLERGO: 📌LEADER trial: LIRAGLUTIDE 📍 18% had history of NYHA class I to III HF 📍 MACE reduction was consistent in patients with (HR 0…
RT @JTLLERGO: 📌LEADER trial: LIRAGLUTIDE 📍 18% had history of NYHA class I to III HF 📍 MACE reduction was consistent in patients with (HR 0…
RT @Drlipid: Cost aside (obviously a major issue), anyone who has diabetes & high CV risk should consider liraglutide or perhaps another GL…
RT @CarreteroJuani: Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure | JACC. GLP1r…
RT @SemergenGTDM: Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure | JACC: Journal…
Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure | JACC: Journal of the American College of Cardiology https://t.co/3LFE3j5boG
RT @JTLLERGO: 📌LEADER trial: LIRAGLUTIDE 📍 18% had history of NYHA class I to III HF 📍 MACE reduction was consistent in patients with (HR 0…
RT @CarreteroJuani: Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure | JACC. GLP1r…
Also consider GLP-1 (semmaglutide) for #obesity treatment - especially if high CV risk.
Cost aside (obviously a major issue), anyone who has diabetes & high CV risk should consider liraglutide or perhaps another GLP-1 RA - Latest data from LEADER - https://t.co/dNqOgiYCTY
RT @JTLLERGO: 📌LEADER trial: LIRAGLUTIDE 📍 18% had history of NYHA class I to III HF 📍 MACE reduction was consistent in patients with (HR 0…
Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure | JACC. GLP1ra in HF?? Of course @Diabetes_SEMI @chemachir @fjcarrascos @joscarlor2 https://t.co/tPhm8juitM
RT @JTLLERGO: 📌LEADER trial: LIRAGLUTIDE 📍 18% had history of NYHA class I to III HF 📍 MACE reduction was consistent in patients with (HR 0…
RT @JTLLERGO: 📌LEADER trial: LIRAGLUTIDE 📍 18% had history of NYHA class I to III HF 📍 MACE reduction was consistent in patients with (HR 0…
📌LEADER trial: LIRAGLUTIDE 📍 18% had history of NYHA class I to III HF 📍 MACE reduction was consistent in patients with (HR 0.81) and without (HR 0.88) a history of HF @JACCJournals @secardiologia https://t.co/HzzudOYoK6 https://t.co/3dN3ezeniW